Table 3.
Rapamycin | Bladder infusion Chemotherapy | GC/GCa chemotherapy | CNI drugs | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OS | RFS | PFS | OS | RFS | PFS | OS | RFS | PFS | OS | RFS | PFS | ||
BC | |||||||||||||
T1 and lower stage | - | - | - | - | 0.071 | 0.4 | - | - | - | 0.281 | 0.755 | 0.937 | |
UTUC | |||||||||||||
T1 and lower stage | 0.057 | - | 0.122 | 0.343 | - | 0.199 | - | - | - | 0.187 | - | 0.017 | |
T2 and higher stage | 0.317 | - | 0.026 | - | - | - | 0.132 | - | 0.521 | - | - | - | |
BC + UTUC | |||||||||||||
T1 and lower stage | 0.225 | 0.98 | 0.274 | 0.665 | 0.778 | 0.228 | - | - | - | 0.672 | 0.361 | 0.895 | |
T2 and higher stage | 0.602 | 0.362 | 0.436 | 0.284 | 0.697 | 0.825 | 0.507 | 0.885 | 0.436 | - | - | - |
BC: Bladder Carcinoma; UTUC: Upper-tract Urocilial Carcinoma